Other Expense (Income)

3 Months Ended

Mar. 31, 2024

Other Income and Expenses [Abstract]

Other expense (income) consists of:


	Three Months Ended March 31,
($ in millions)	2024		2023

Loss on disposal of plant	$	—	$	9.4
Foreign exchange transaction losses	1.2		0.9
Contingent consideration	1.0		0.3
Asset impairments	0.6		1.9



Other items	0.3		0.4
Total other expense (income)	$	3.1	$	12.9

Loss on Disposal of Plant

During the three months ended March 31, 2023, the Company recorded expense of $9.4 million within other expense (income), as a result of the sale of one of the Company's manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

Contingent Consideration

Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.

Restructuring and Related Charges

In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $22 million to $24 million, with annualized savings in the range of $22 million to $24 million.

The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:


($ in millions)	Severance and benefits		Other charges		Total
Balance, December 31, 2023	$	3.0	$	—	$	3.0
(Credits) charges	—		—		—
Cash payments	(0.3)		—		(0.3)

Balance, March 31, 2024	$	2.7	$	—	$	2.7